Review article: Pathogenesis and management of gastric carcinoid tumours

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 9, 2006, Pages 1305-1320

  Burkitt, M D ^a   Pritchard, D M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CHOLECYSTOKININ B RECEPTOR; CYTOKINE; DNA; GASTRIN; GELATINASE B; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; KI 67 ANTIGEN; MATRILYSIN; METHIONINE; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN; PROTEIN BCL 2; PROTEIN CINC 2BETA; PROTEIN KINASE C; PROTEIN MEN 1; PROTEIN P53; PROTEIN REG; PROTON PUMP INHIBITOR; SEROTONIN; SOMATOSTATIN DERIVATIVE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACHLORHYDRIA; ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURGERY; CARCINOID; CLINICAL FEATURE; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HYPERGASTRINEMIA; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; ZOLLINGER ELLISON SYNDROME;

CARCINOID TUMOR; HUMANS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33750000586     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03130.x     Document Type: Review

References (108)

1. Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumours: In Collaboration with 9 Pathologists from 4 Countries. Berlin, New York: Springer, 1999.
2. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003; 12: 153-72.
3. Delle FG, Capurso G, Annibale B, Panzuto F. Gastric neuroendocrine tumors. Neuroendocrinology 2004; 80 (Suppl. 1): 16-9.
4. Delle FG, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 2005; 19: 659-73.
5. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994-1006.
6. Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 2001; 13: 1449-56.
7. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 64-73.
8. Hosokawa O, Kaizaki Y, Hattori M, et al. Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer 2005; 8: 42-6.
9. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83: 43-83.
10. Bordi C, Corleto VD, Azzoni C, et al. The antral mucosa as a new site for endocrine tumors in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndromes. J Clin Endocrinol Metab 2001; 86: 2236-42.
11. Bordi C, Falchetti A, Azzoni C, et al. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 1997; 21: 1075-82.
12. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 2004; 136: 1267-74.
13. Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours. Digestion 1995; 56: 455-62.
14. Ooi A, Ota M, Katsuda S, Nakanishi I, Sugawara H, Takahashi I. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocr Pathol 1995; 6: 229-37.
15. Abraham SC, Carney JA, Ooi A, Choti MA, Argani P. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol 2005; 29: 969-75.
16. Harvey RF, Bradshaw MJ, Davidson CM, Wilkinson SP, Davies PS. Multifocal gastric carcinoid tumours, achlorhydria, and hypergastrinaemia. Lancet 1985; 1: 951-4.
17. Dockray GJ, Varro A, Dimaline R, Wang T. The gastrins: their production and biological activities. Annu Rev Physiol 2001; 63: 119-39.
18. Dockray GJ. Clinical endocrinology and metabolism. Gastrin Best Pract Res Clin Endocrinol Metab 2004; 18: 555-68.
19. Koh TJ, Goldenring JR, Ito S, et al. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology 1997; 113: 1015-25.
20. Friis-Hansen L, Sundler F, Li Y, et al. Impaired gastric acid secretion in gastrin-deficient mice. Am J Physiol 1998; 274: G561-8.
21. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hyper-gastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000; 118: 36-47.
22. Tang LH, Luque EA, Efstathiou JA, et al. Gastrin receptor expression and function during rapid transformation of the enterochromaffin-like cells in an African rodent. Regul Pept 1997; 72: 9-18.
23. Schaffer K, McBride EW, Beinborn M, Kopin AS. Interspecies polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B/gastrin receptor. J Biol Chem 1998; 273: 28779-84.
24. Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK 16: 288-98.
25. Agarwal SK, Kennedy PA, Scacheri PC, et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 2005; 37: 369-74.
26. D'Adda T, Keller G, Bordi C, Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999; 79: 671-7.
27. Terazono K, Yamamoto H, Takasawa S, et al. A novel gene activated in regenerating islets. J Biol Chem 1988; 263: 2111-4.
28. Watanabe T, Yonekura H, Terazono K, Yamamoto H, Okamoto H. Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene. J Biol Chem 1990; 265: 7432-9.
29. Higham AD, Bishop LA, Dimaline R, et al. Mutations of RegIalpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology 1999; 116: 1310-8.
30. Fukui H, Kinoshita Y, Maekawa T, et al. Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology 1998; 115: 1483-93.
31. Kazumori H, Ishihara S, Hoshino E, et al. Neutrophil chemoattractant 2 beta regulates expression of the Reg gene in injured gastric mucosa in rats. Gastroenterology 2000; 119: 1610-22.
32. Miyaoka Y, Kadowaki Y, Ishihara S, et al. Transgenic overexpression of Reg protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages. Oncogene 2004; 23: 3572-9.
33. Azzoni C, Doglioni C, Viale G, et al. Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids. Am J Surg Pathol 1996; 20: 433-41.
34. Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 2005; 128: 1567-78.
35. Kagawa J, Honda S, Kodama M, Sato R, Murakami K, Fujioka T. Enterocromaffin-like cell tumor induced by Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2002; 7: 390-7.
36. Sato Y, Iwafuchi M, Ueki J, et al. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci 2002; 47: 579-85.
37. Wroblewski LE, Pritchard DM, Carter S, Varro A. Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem J 2002; 365: 873-9.
38. Varro A, Pritchard DM, McCaig C, et al. The role of matrix metalloprotease-7 in redefining the gastric microenvironment in response to gastrin and H. pylori. Gut 2006; 55: A114.
39. Varro A, Hemers E, Archer D, et al. Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin. Gastroenterology 2002; 123: 271-80.
40. Peny MO, Donckier V, Gelin M, Haot J, Noel JC. Sporadic carcinoid of the stomach: a highly proliferative disease with a probable role for p53 protein dysregulation. Eur J Gastroenterol Hepatol 1999; 11: 677-9.
41. Pizzi S, Azzoni C, Bassi D, Bottarelli L, Milione M, Bordi C. Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer 2003; 98: 1273-82.
42. Nishikura K, Watanabe H, Iwafuchi M, Fujiwara T, Kojima K, Ajioka Y. Carcinogenesis of gastric endocrine cell carcinoma: analysis of histopathology and p53 gene alteration. Gastric Cancer 2003; 6: 203-9.
43. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-59.
44. Borch K, Skarsgard J, Franzen L, Mardh S, Rehfeld JF. Benign gastric polyps: morphological and functional origin. Dig Dis Sci 2003; 48: 1292-7.
45. Gencosmanoglu R, Sen-Oran E, Kurtkaya-Yapicier O, Avsar E, Sav A, Tozun N. Gastric polypoid lesions: analysis of 150 endoscopic polypectomy specimens from 91 patients. World J Gastroenterol 2003; 9: 2236-9.
46. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 23-32.
47. Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005; 19: 1610-2.
48. Laxen F, Sipponen P, Ihamaki T, Hakkiluoto A, Dortscheva Z. Gastric polyps; their morphological and endoscopical characteristics and relation to gastric carcinoma. Acta Pathol Microbiol Immunol Scand [A] 1982; 90: 221-8.
49. Ljubicic N, Kujundzic M, Roic G, et al. Benign epithelial gastric polyps-frequency, location, and age and sex distribution. Coll Antropol 2002; 26: 55-60.
50. Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases. Eur J Cancer Prev 2003; 12: 191-4.
51. Rindi G, Azzoni C, La RS, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116: 532-42.
52. Roncoroni L, Costi R, Canavese G, Violi V, Bordi C. Carcinoid tumor associated with vascular malformation as a cause of massive gastric bleeding. Am J Gastroenterol 1997; 92: 2119-21.
53. Dallal HJ, Ravindran R, King PM, Phull PS. Gastric carcinoid tumour as a cause of severe upper gastrointestinal haemorrhage. Endoscopy 2003; 35: 716.
54. Bordi C, D'Adda T, Azzoni C, Canavese G, Brandi ML. Gastrointestinal endocrine tumors: Recent developments. Endocr Pathol 1998; 9: 99-115.
55. Johansson H, Wilander E. A clinical study of 30 gastric carcinoids. Ups J Med Sci 1982; 87: 135-42.
56. Modlin IM, Gilligan CJ, Lawton GP, Tang LH, West AB, Darr U. Gastric carcinoids. The Yale Experience. Arch Surg 1995; 130: 250-5.
57. Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994; 73: 2053-8.
58. Oates JA, Sjoerdsma A. A unique syndrome associated with secretion of 5-hydroxytryptophan by metastatic gastric carcinoids. Am J Med 1962; 32: 333-42.
59. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004; 11: 1-18.
60. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-51.
61. Stone PA, Hofeldt MJ, Campbell JE, Vedula G, DeLuca JA, Flaherty SK. Meckel diverticulum: ten-year experience in adults. South Med J 2004; 97: 1038-41.
62. Solcia E, Fiocca R, Villani L, Luinetti O, Capella C. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 1995; 19 (Suppl. 1): S1-S7.
63. Wilander E, Portela-Gomes G, Grimelius L, Westermark P. Argentaffin and argyrophil reactions of human gastrointestinal carcinoids. Gastroenterology 1977; 73: 733-6.
64. Bordi C, Yu JY, Baggi MT, et al. Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 1991; 67: 663-72.
65. Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79: 769-94.
66. Rehm H, Wiedenmann B, Betz H. Molecular characterization of synaptophysin, a major calcium-binding protein of the synaptic vesicle membrane. Embo J 1986; 5: 535-41.
67. Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 1985; 41: 1017-28.
68. Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 1986; 83: 3500-4.
69. Rindi G, Buffa R, Sessa F, Tortora O, Solcia E. Chromogranin A, B and C immunoreactivities of mammalian endocrine cells. Distribution, distinction from costored hormones/prohormones and relationship with the argyrophil component of secretory granules. Histochemistry 1986; 85: 19-28.
70. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996; 93: 5166-71.
71. Prinz C, Zanner R, Gerhard M, et al. The mechanism of histamine secretion from gastric enterochromaffin-like cells. Am J Physiol 1999; 277: C845-55.
72. Rindi G, Paolotti D, Fiocca R, Wiedenmann B, Henry JP, Solcia E. Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Arch 2000; 436: 217-23.
73. Annibale B, Lahner E, Negrini R, et al. Lack of specific association between gastric autoimmunity hallmarks and clinical presentations of atrophic body gastritis. World J Gastroenterol 2005; 11: 5351-7.
74. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 2001; 80: 189-222.
75. Ba-Ssalamah A, Prokop M, Uffmann M, Pokieser P, Teleky B, Lechner G. Dedicated multidetector CT of the stomach: spectrum of diseases. Radiographics 2003; 23: 625-44.
76. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog. J Steroid Biochem Mol Biol 1990; 37: 1079-82.
77. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-9.
78. Reubi JC, Krenning E, Lamberts SW, Kvols L. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990; 37: 1073-7.
79. Gibril F, Reynolds JC, Lubensky IA, et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 2000; 41: 1646-56.
80. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-400.
81. Orlefors H, Sundin A, Lu L, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with (11)C-5- hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33: 60-65.
82. Vander Noot III MR, Eloubeidi MA, Chen VK, et al. Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer 2004; 102: 157-63.
83. Voss M, Hammel P, Molas G, et al. Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut 2000; 46: 244-9.
84. Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 229-39.
85. Higham AD, Dimaline R, Varro A, et al. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998; 114: 817-22.
86. Bashir S, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther 2002; 16: 1367-82.
87. Peracchi M, Gebbia C, Basilisco G, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152: 443-8.
88. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622-8.
89. Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 2003; 35: 203-6.
90. Richards AT, Hinder RA, Harrison AC. Gastric carcinoid tumours associated with hypergastrinaemia and pernicious anaemia - regression of tumors by antrectomy. A case report. S Afr Med J 1987; 72: 51-3.
91. Kern SE, Yardley JH, Lazenby AJ, et al. Reversal by antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: a morphometric study. Mod Pathol 1990; 3: 561-6.
92. D'Adda T, Pilato FP, Sivelli R, Azzoni C, Sianesi M, Bordi C. Gastric carcinoid tumor and its precursor lesions. Ultrastructural study of a case before and after antrectomy. Arch Pathol Lab Med 1994; 118: 658-63.
93. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102: 1409-18.
94. Richards ML, Gauger P, Thompson NW, Giordano TJ. Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World J Surg 2004; 28: 652-8.
95. Kaehler G, Grobholz R, Langner C, Suchan K, Post S. A new technique of endoscopic full-thickness resection using a flexible stapler. Endoscopy 2006; 38: 86-9.
96. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 2004; 39: 621-8.
97. Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scand J Gastroenterol 2005; 40: 1269-74.
98. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000; 343: 551-4.
99. Caplin ME, Hodgson HJ, Dhillon AP, et al. Multimodality treatment for gastric carcinoid tumor with liver metastases. Am J Gastroenterol 1998; 93: 1945-8.
100. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 (Suppl. 4): iv1-16.
101. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003; 17: 437-44.
102. Kvols LK, Martin JK, Marsh HM, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 1985; 313: 1229-30.
103. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663-6.
104. Platt AJ, Heddle RM, Rake MO, Smedley H. Ondansetron in carcinoid syndrome. Lancet 1992; 339: 1416.
105. Schworer H, Munke H, Stockmann F, Ramadori G. Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine. Am J Gastroenterol 1995; 90: 645-8.
106. Wymenga AN, de Vries EG, Leijsma MK, Kema IP, Kleibeuker JH. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer 1998; 34: 1293-4.
107. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991; 67: 33-36.
108. Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 265-76.